Amgen Inc.
GROWTH DIFFERENTIATION FACTOR 15 COMBINATION THERAPY
Last updated:
Abstract:
The present disclosure provides combination therapy with GDF15 molecules. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region, optionally via a linker. In one embodiment, combination therapy comprises administration of a GDF15 molecule with a GLP-1R agonist. In another embodiment, combination therapy comprises administration of a GDF15 molecule with a GIPR antagonist.
Status:
Application
Type:
Utility
Filling date:
6 Mar 2020
Issue date:
19 May 2022